Shares of Xeris Biopharma Holdings, Inc. (XERS) are up 12% on Wednesday after the company announced that it has entered into an exclusive worldwide license agreement with Amgen to develop, manufacture, and commercialize a subcutaneous formulation of teprotumumab, also known as TEPEZZA.
XERS is trading on the Nasdaq at $2.71, up 12.44% or $0.30 per share. It has traded between $1.06 and $3.07 in the past 52-week period.
This formulation will use Xeris' XeriJect technology and will be specifically targeted towards treating Thyroid Eye Disease (TED), which is a rare autoimmune disease that is serious, progressive, and potentially vision-threatening.
The License Agreement between the two companies is set to be beneficial for Xeris as it has the potential to receive $75 million in development and regulatory milestones, along with sales-based milestones.
Additionally, Xeris will be receiving escalating single-digit royalties based on future sales of TEPEZZA using the XeriJect technology.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.